• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

1/2期DREAMM-6试验A组结果：复发/难治性多发性骨髓瘤患者使用贝兰他单抗莫福汀联合来那度胺及地塞米松治疗。

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

作者信息

Popat Rakesh, Augustson Bradley, Gironella Mercedes, Lee Cindy, Cannell Paul, Patel Nashita, Kasinathan Ravi S, Rogers Rachel, Shaikh Mehreen, Curry Amy, Carreño Fernando, Roy-Ghanta Sumita, Opalinska Joanna, Quach Hang

机构信息

NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.

Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, WA, Australia.

出版信息

Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y.

DOI:10.1038/s41408-024-01155-y
PMID:39433730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11494064/
Abstract

[Image: see text]

摘要

[图像：见正文]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c98/11494064/94aa286d0e29/41408_2024_1155_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c98/11494064/94aa286d0e29/41408_2024_1155_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c98/11494064/94aa286d0e29/41408_2024_1155_Fig1_HTML.jpg

相似文献

1
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.1/2期DREAMM-6试验A组结果：复发/难治性多发性骨髓瘤患者使用贝兰他单抗莫福汀联合来那度胺及地塞米松治疗。
Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y.
2
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.单药贝兰他单抗mafodotin 与泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性（DREAMM-3）：一项开放标签、随机、3 期研究。
Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
3
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
4
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤患者中，针对贝兰他单抗mafodotin 的治疗剂量选择进行暴露-反应分析。
Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4.
5
Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.来自DREAMM-1和-2研究的复发或难治性多发性骨髓瘤患者中贝兰他单抗莫福汀的浓度-QTc关系。
Br J Clin Pharmacol. 2024 Oct;90(10):2571-2581. doi: 10.1111/bcp.16133. Epub 2024 Jun 23.
6
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.硼替佐米、泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2.
7
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.EMA 审查贝兰他单抗mafodotin（Blenrep）治疗成人复发/难治性多发性骨髓瘤。
Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.
8
Belantamab mafodotin for the treatment of multiple myeloma.贝兰他单抗马妥昔单抗用于多发性骨髓瘤的治疗。
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146.
9
Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.DREAMM-2研究中，患者报告的使用贝兰他单抗莫福汀治疗复发/难治性多发性骨髓瘤期间及之后的体验。
Front Oncol. 2023 Dec 7;13:1274659. doi: 10.3389/fonc.2023.1274659. eCollection 2023.
10
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.难治性多发性骨髓瘤中贝兰他单抗马妥莫单抗、泊马度胺和地塞米松的疗效：一项 1/2 期试验。
Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4.

引用本文的文献

1
Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.优化贝兰他单抗莫福汀治疗复发或难治性多发性骨髓瘤：真实世界回顾性研究中剂量调整对不良事件和血液学反应的影响
Cancers (Basel). 2025 Jul 19;17(14):2398. doi: 10.3390/cancers17142398.

本文引用的文献

1
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.硼替佐米、泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2.
2
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.贝兰他单抗马妥昔单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
3
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study.
贝兰他单抗莫福汀、来那度胺和地塞米松用于新诊断的不适宜移植的多发性骨髓瘤患者：一项I/II期研究的第1部分结果
Haematologica. 2024 Aug 1;109(8):2594-2605. doi: 10.3324/haematol.2023.284347.
4
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.在新诊断的不适于移植的多发性骨髓瘤患者中使用贝兰他单抗马福多汀、来那度胺和地塞米松：来自1/2期研究第1部分的贝兰他单抗马福多汀相关眼部不良事件及其对日常功能影响的分析。
Am J Hematol. 2024 Mar;99(3):502-504. doi: 10.1002/ajh.27219. Epub 2024 Jan 25.
5
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.难治性多发性骨髓瘤中贝兰他单抗马妥莫单抗、泊马度胺和地塞米松的疗效：一项 1/2 期试验。
Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4.
6
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.单药贝兰他单抗mafodotin 与泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性（DREAMM-3）：一项开放标签、随机、3 期研究。
Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
7
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.单药贝兰他单抗mafodotin 治疗复发/难治性多发性骨髓瘤患者：DREAMM-2 试验的最终分析。
Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25.
8
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
9
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.新型抗 B 细胞成熟抗原抗体药物偶联物（GSK2857916）选择性诱导多发性骨髓瘤细胞的杀伤。
Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25.